Finasteride Cost in Kansas 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Does Finasteride Actually Cost in Kansas Right Now?

Generic finasteride is available at most Kansas retail pharmacies for approximately $12 per month in 2026, making it one of the more affordable prescription hair-loss and BPH treatments on the market. Brand-name Propecia (Merck) carries a manufacturer list price near $85 per month. Most prescribers and pharmacists in Kansas recommend starting with the generic unless a specific formulation is required.

Finasteride works by inhibiting the Type II 5-alpha-reductase enzyme, which converts testosterone to dihydrotestosterone (DHT). Reducing DHT is central to slowing AGA progression and shrinking an enlarged prostate. The FDA approved the 5 mg tablet (Proscar) for benign prostatic hyperplasia in 1992 and the 1 mg tablet (Propecia) for male-pattern hair loss in 1997, both based on placebo-controlled trials demonstrating statistically significant efficacy [1].

The landmark Kaufman et al. study (J Am Acad Dermatol 1998, N=1,553) showed that finasteride 1 mg daily produced a statistically significant increase in hair count versus placebo at 12 months (P<0.001), with 48% of men showing improvement on global photographic assessment at 24 months compared with 7% on placebo [2]. That evidence base underpins the drug's continued first-line status in AGA guidelines [3].

Prices across specific Kansas cities in 2026 differ by no more than a few dollars. Wichita, Overland Park, Kansas City KS, and Topeka pharmacies all land close to the $12 benchmark for a 30-day supply of generic 1 mg when a GoodRx or similar discount card is used. Without any discount program, retail cash prices at large chain pharmacies in Kansas can run $18 to $28 per month for the generic [4].

The FDA's current prescribing information confirms finasteride's approved indications and dosing, which Kansas pharmacies dispense under standard state pharmacy board rules [1].

Generic vs. Brand Finasteride: Which Should Kansas Patients Choose?

Generic finasteride tablets are bioequivalent to Propecia under FDA standards. The price difference is significant. At $12 per month for generic versus $85 per month for brand, a Kansas patient choosing brand over generic pays roughly $876 more per year for identical therapeutic effect [1].

The FDA defines bioequivalence as a 90% confidence interval for the ratio of geometric means of AUC and Cmax falling within 80% to 125% of the reference product [5]. Every generic finasteride on the US market has met that standard before receiving approval. There is no published evidence that brand Propecia outperforms therapeutically equivalent generics in hair-count or DHT-suppression outcomes [2].

A few patients do report tolerability differences between manufacturers, possibly related to inactive excipients. If a Kansas patient experiences an unexpected adverse effect after switching manufacturers, the prescribing clinician may document the concern and authorize brand-name dispensing, though insurance coverage for the brand at that point depends on the specific plan's step-therapy policy [6].

Finasteride tablets should not be crushed or handled by pregnant women due to the risk of fetal harm from DHT suppression during male genital development, a warning carried in all FDA labeling regardless of brand or generic source [1].

Kansas Medicaid Coverage for Finasteride: What the Formulary Actually Says

Kansas Medicaid (KanCare) does not cover finasteride for androgenetic alopecia. The drug is classified as a cosmetic treatment for AGA under standard Medicaid exclusions, which mirror federal guidelines permitting states to exclude drugs used for cosmetic purposes [7].

Coverage for the BPH indication (5 mg) is also not guaranteed under KanCare's standard formulary. Kansas Medicaid managed-care organizations (Sunflower Health Plan, Aetna Better Health of Kansas, UnitedHealthcare Community Plan) each maintain their own preferred drug lists. A prior authorization request citing a documented BPH diagnosis, symptom score, and trial of alpha-blocker therapy may result in coverage approval, but approval is not automatic [8].

The Centers for Medicare and Medicaid Services (CMS) guidance notes that states may cover medications for non-cosmetic indications even when the same drug is excluded for cosmetic use, meaning a KanCare enrollee with BPH has a stronger formulary argument than one seeking coverage for hair loss [7].

For KanCare enrollees who are denied coverage, the $12 cash price with a discount card is often lower than many covered-drug copays, making an out-of-pocket purchase practical. Patients can ask their pharmacist to run both the Medicaid claim and a GoodRx price and take whichever is cheaper [4].

The Kansas Health Institute tracks KanCare formulary updates annually; patients and prescribers can request a current preferred drug list directly from their managed care organization [8].

Is Compounded Finasteride Legal in Kansas?

Compounded finasteride prepared by a 503A pharmacy is legal in Kansas. A 503A pharmacy compounds for individual patients under a valid prescription, operating under state pharmacy board oversight and federal USP standards [9].

The cost sits around $45 per month, which is higher than generic tablets but lower than brand Propecia. Why would a patient choose the compounded version? Three main reasons appear in clinical practice. First, some patients request topical finasteride formulations (solutions or gels) to reduce systemic absorption and potentially minimize sexual side effects, though clinical data on topical bioavailability relative to oral dosing remain limited [10]. Second, dose customization outside the standard 1 mg or 5 mg increments is sometimes requested. Third, combination products (for example, finasteride plus minoxidil in a single topical base) are only available through compounding [11].

The FDA does not recognize an FDA-approved equivalent for topical finasteride, which means 503A pharmacies may compound it without triggering the "essentially a copy" restriction that applies to oral tablets [9]. The Kansas State Board of Pharmacy requires compounding pharmacies to hold a valid state license and comply with USP Chapter 795 (non-sterile) or 797 (sterile) standards as applicable [12].

503B outsourcing facilities are a separate category and are federally registered with the FDA; they may produce larger batches without patient-specific prescriptions [9]. Kansas patients receiving finasteride from a 503B facility should confirm the facility's FDA registration status at the FDA's online database [1].

How Private Insurance Covers Finasteride in Kansas

Most private insurance plans in Kansas follow the same logic as Medicaid: they exclude finasteride for AGA (cosmetic) and may cover it for BPH with prior authorization. The specifics depend on whether the plan is fully insured (subject to Kansas Insurance Department oversight) or self-insured under ERISA (governed by federal law, not state insurance mandates) [6].

Kansas does not have a state mandate requiring coverage of finasteride for either AGA or BPH, so plan design is largely at the employer or insurer's discretion [6].

For BPH coverage, the typical documentation required includes an ICD-10 code of N40.1 (BPH with lower urinary tract symptoms), a recent International Prostate Symptom Score, and evidence of alpha-blocker therapy if the insurer requires step therapy. Blue Cross Blue Shield of Kansas, Aetna, Cigna, and UnitedHealthcare all have prior authorization criteria available through their provider portals [6].

When finasteride is covered for BPH, the typical Tier 1 or Tier 2 copay runs $5 to $15 per month for generic, well below the cash price. Brand Propecia, when covered at all, typically sits on Tier 3 or Tier 4 with a copay of $40 to $75 per month [6].

The American Urological Association guideline on BPH management recommends 5-alpha-reductase inhibitors, including finasteride, as a treatment option for patients with bothersome lower urinary tract symptoms and enlarged prostate volume (>30 mL), which supports medical necessity arguments during prior authorization appeals [13].

Discount Programs and the Cheapest Path to Finasteride in Kansas

The cheapest way for most uninsured or underinsured Kansas patients to obtain finasteride is a GoodRx or similar discount coupon at a high-volume retail chain pharmacy, targeting the $12 per month price point [4].

Merck's patient assistance program (Merck Patient Assistance Program, formerly the ACT program) provides brand Propecia or Proscar at no cost to patients who meet income criteria, generally at or below 200% of the federal poverty level. Applications are submitted through Merck's website or through a social worker [14].

NeedyMeds and RxAssist maintain databases of manufacturer assistance programs and may list additional Kansas-specific resources. The Kansas Insurance Department's Consumer Assistance line (1-800-432-2484) can also guide patients toward state pharmaceutical assistance options [8].

GoodRx has published price data showing finasteride 1 mg (30 tablets) at select Wichita and Overland Park pharmacies as low as $9 to $11 per month when using their free coupon in 2025, consistent with the $12 benchmark [4]. Prices fluctuate by pharmacy and by month, so comparing prices at multiple ZIP codes within Kansas before filling is worthwhile.

The Mark Cuban Cost Plus Drugs platform (costplusdrugs.com) listed finasteride 1 mg at approximately $6 for 30 tablets as of mid-2025, available via mail order to Kansas addresses. Patients should confirm current pricing and mail-order licensing directly on the platform [15].

HealthRX Kansas Finasteride Cost Decision Framework

Use this sequential checklist to identify the lowest-cost path:

1. Do you have private insurance? Request prior authorization for BPH (if applicable). If denied or if indication is AGA, proceed to step 2.
2. Do you qualify for KanCare? Request a formulary exception for BPH with ICD-10 N40.1 documentation. If denied or if indication is AGA, proceed to step 3.
3. Do you meet Merck PAP income criteria? Apply for free brand-name product. If not eligible, proceed to step 4.
4. Compare generic cash prices. Run GoodRx, RxSaver, and Cost Plus Drugs at your nearest Kansas pharmacy. Target $12 per month or less.
5. If topical or combination formulation is clinically indicated, obtain a prescription for a 503A compounded product (~$45/month) from a Kansas-licensed compounding pharmacy.

Telehealth Prescribing of Finasteride in Kansas

Telehealth prescribing of finasteride is fully legal in Kansas as of 2026. Kansas enacted telehealth parity legislation requiring that services delivered via telehealth meet the same standard of care as in-person visits [16]. A licensed Kansas prescriber (MD, DO, PA, APRN) may conduct a synchronous video visit, evaluate the patient, and issue a finasteride prescription electronically to any Kansas-licensed pharmacy [16].

The Kansas State Board of Healing Arts requires that a valid prescriber-patient relationship be established before controlled substances are prescribed via telehealth, but finasteride is not a controlled substance, so that restriction does not apply here [16].

HealthRX and similar telehealth platforms serving Kansas can connect patients with a licensed clinician within 24 to 48 hours in most cases. The initial visit typically costs $30 to $75 without insurance. Some platforms bundle the consultation fee with a monthly medication subscription, which may change the effective per-month cost calculation [4].

A 2021 systematic review in JAMA Dermatology (Juhasz et al.) found that teledermatology services for hair loss produced patient satisfaction scores and diagnostic concordance rates comparable to in-person visits, though the evidence base was limited to observational studies [17]. Kansas patients in rural counties (for example, Greeley, Hamilton, or Stanton counties) benefit most from telehealth access given limited local dermatology availability [16].

Prescriptions issued via telehealth are treated identically by Kansas pharmacies to those written in person. No additional documentation is required at the pharmacy counter [16].

Finasteride Efficacy: What Kansas Patients Can Expect Clinically

Understanding efficacy helps patients decide whether the cost is justified for their specific situation.

For AGA, the Kaufman et al. (1998) 24-month trial (N=1,553) showed a mean increase of 107 hairs in a 1-inch-diameter vertex scalp area in finasteride-treated men versus a mean decrease of 75 hairs in placebo-treated men, a net between-group difference of 182 hairs per square inch (P<0.001) [2]. Hair loss stabilized in 83% of treated men at 24 months versus 28% on placebo [2].

For BPH, the PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040 to 4 years) demonstrated that finasteride 5 mg reduced prostate volume by 18% and decreased the risk of acute urinary retention by 57% compared with placebo (P<0.001) [18]. The American Urological Association incorporates these data into its BPH guideline, recommending 5-alpha-reductase inhibitors for patients with prostate volume above 30 mL [13].

Sexual side effects (decreased libido, erectile dysfunction, ejaculatory disorder) occurred in 3.8% of finasteride-treated versus 2.1% of placebo-treated men in the original Propecia trials, with most resolving on discontinuation [1]. Post-marketing reports of persistent sexual dysfunction after stopping finasteride (sometimes called post-finasteride syndrome) are under ongoing FDA review; the FDA added a label update in 2012 noting this possibility [1].

Kansas clinicians following the American Academy of Dermatology AGA treatment guidelines should discuss these risks with patients before prescribing, document the conversation, and reassess at 3 and 12 months [3].

How Long Before Finasteride Works: Setting Kansas Patient Expectations

Onset of visible effect takes time. Patients should understand this before committing to the monthly cost.

Hair shedding may temporarily increase during the first 2 to 3 months as the follicular cycle resets, a phenomenon consistent across the key trials [2]. Stabilization of hair loss is generally detectable by month 6 of consistent daily dosing. Measurable regrowth, when it occurs, is typically documented at the 12-month mark [2].

Patients who discontinue finasteride lose the protective effect within 6 to 12 months, with hair density returning toward pre-treatment baseline [1]. This means the $12 per month cash cost is an ongoing monthly expense, not a finite treatment course.

For BPH, symptom improvement (measured by International Prostate Symptom Score reduction) begins within 3 to 6 months, and maximum prostate volume reduction occurs by 6 months of continuous therapy [18].

The FDA label states that clinical benefit in AGA should be reassessed at 12 months; patients who show no response at 12 months are unlikely to benefit from continued treatment [1]. Kansas prescribers should schedule a 12-month follow-up visit (telehealth or in-person) to evaluate response before renewing long-term prescriptions [3].

The Endocrine Society's clinical practice guideline on transgender and intersex care also addresses 5-alpha-reductase inhibitors, providing context for off-label use scenarios that some Kansas clinicians manage within their practice [19].

Drug Interactions and Monitoring for Kansas Patients

Finasteride has a limited drug-interaction profile compared with many other medications. It does not significantly affect CYP450 enzymes at therapeutic doses, so interactions with common medications (statins, antihypertensives, SSRIs) are not expected based on published pharmacokinetic data [1].

One interaction worth noting: finasteride lowers PSA (prostate-specific antigen) values by approximately 50% after 6 months of continuous use [1]. Kansas clinicians ordering PSA for prostate cancer screening in a patient on finasteride should double the measured PSA value to approximate the untreated baseline, consistent with the FDA label recommendation [1]. Failure to account for this can lead to false reassurance on a PSA screen [20].

The FDA Adverse Event Reporting System (FAERS) database contains post-marketing reports of depression and suicidal ideation associated with finasteride, prompting the FDA to add a warning to the label in 2022 [1]. Kansas prescribers should screen for mood changes at follow-up visits, particularly during the first 12 months of therapy [3].

Liver function monitoring is not routinely required given finasteride's metabolism profile, but clinicians managing patients with hepatic impairment should note that the drug is extensively metabolized by CYP3A4 in the liver and exposure may be increased in severe hepatic disease [1].